Literature DB >> 24935366

Histopathologic characterization of prostate diseases in Madinah, Saudi Arabia.

Abdulkader Albasri1, Abeer El-Siddig, Akbar Hussainy, Mervat Mahrous, Abdulaziz Abdullah Alhosaini, Ahmed Alhujaily.   

Abstract

AIMS: To delineate the histopathological pattern of prostate diseases and to highlight age variations in prostate specific antigen (PSA) values and histopathological features.
MATERIALS AND METHODS: A retrospective review was made of all prostate biopsy reports seen between January 2006 and December 2013 at the King Fahad Hospital, Madinah, Saudi Arabia. Prostate lesions were tabulated and classified into benign and malignant groups. Histological scoring of adenocarcinomas was accomplished using the Gleason system. PSA values were correlated with Gleason scores.
RESULTS: Of 417 prostate lesions reviewed, 343 (82.3%) were benign and 74 (17.7%) were malignant, giving a benign to malignant ratio of 4.6:1. Benign prostatic hyperplasia (both with and without inflammation) was the commonest prostatic lesion and accounted for 80.3% of all cases and 97.6% of all benign cases. The age range was 20 to 97 years with a mean of 69.2 years and a peak age group at 70-79 years. Seventy one cases of adenocarcinoma accounted for 95.9% of the total of 74 malignant tumors. It showed an age range of 44 to 95 years, a mean age of 70.9 years and peak prevalence in the 80-89 year age group. Gleason score seven was the most frequent (39.4%) in occurrence. Most adenocarcinomas, 41 cases (57.7%), were moderately differentiated (Gleason score of 5-7). PSA values ranged widely between 16-1,865 ng/ml with a mean of 363.4 ng/ml. Elevated PSA (>100 ng/ml) levels were found in 53 (81.6%) patients. There was a statistically significant positive correlation between serum PSA level and Gleason score (p=0.0304).
CONCLUSIONS: Prostatic lesions constitute a significant source of morbidity among adult males in Madinah. Benign prostatic hyperplasia was the commonest benign prostatic lesion and adenocarcinoma was the commonest histological subtype of prostatic cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24935366     DOI: 10.7314/apjcp.2014.15.10.4175

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  6 in total

1.  Histopathological pattern of testicular diseases in western Saudi Arabia.

Authors:  Abdulkader M Albasri; Akbar S Hussainy
Journal:  Saudi Med J       Date:  2018-05       Impact factor: 1.484

2.  Epidemiology of cancer in Saudi Arabia thru 2010-2019: a systematic review with constrained meta-analysis.

Authors:  Wedad Saeed Alqahtani; Nawaf Abdulrahman Almufareh; Dalia Mostafa Domiaty; Gadah Albasher; Manal Abduallah Alduwish; Huda Alkhalaf; Bader Almuzzaini; Salma Sanhaat Al-Marshidy; Rgya Alfraihi; Abdelbaset Mohamed Elasbali; Hussain Gadelkarim Ahmed; Bassam Ahmed Almutlaq
Journal:  AIMS Public Health       Date:  2020-09-11

3.  A Clinicopathological Profile of Prostate Cancer in Trinidad and Tobago.

Authors:  Ian Hosein; Rajendra Sukhraj; Lester Goetz; Nastassia Rambarran; Satyendra Persaud
Journal:  Adv Urol       Date:  2016-07-17

4.  Histopathological diagnoses and patterns in transrectal ultrasound-guided prostatic biopsy series from a large tertiary care center in Saudi Arabia.

Authors:  Ali A Alsulihem; Muaiqel Al-Muaiqel; Abdulrahman Alsunbul; Abdulrahman Bin Jawhar; Abdullah Al-Dughaiman; Khalid K Bedaiwi; Sami Al-Rashidi; Faris Al-Harbi; Hosam S El-Tholoth; Mohammad Al-Hagbani; Bader Milibary; Abdullah M Alghamdi
Journal:  Urol Ann       Date:  2020-11-04

5.  Histopathological features of breast cancer in Al-Madinah region of Saudi Arabia.

Authors:  Abdulkader Albasri; Akbar S Hussainy; Ibrahim Sundkji; Ahmed Alhujaily
Journal:  Saudi Med J       Date:  2014-12       Impact factor: 1.484

6.  A histopathological study of prostate lesions in Lagos, Nigeria: A private practice experience.

Authors:  Chukwuemeka Charles Nwafor; Olalekan Samuel Keshinro; Emmanuel Kunle Abudu
Journal:  Niger Med J       Date:  2015 Sep-Oct
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.